Clinical Trials Logo

Clinical Trial Summary

The primary objective is the observation and description of the preliminary efficacy of resiquimod gel 0.06% on a single nodular basal cell carcinoma (nBCC) in a small group of patients.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01808950
Study type Interventional
Source Spirig Pharma Ltd.
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date January 2013
Completion date March 2014

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04552990 - Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma Phase 2
Completed NCT02270645 - Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser N/A
Completed NCT02018679 - Er:YAG Ablative Fractional Laser Assisted-Photodynamic Therapy Versus Photodynamic Therapy for Basal Cell Carcinoma Phase 1
Recruiting NCT05157763 - A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma Phase 1/Phase 2
Active, not recruiting NCT02242929 - Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma Phase 3
Recruiting NCT04744935 - Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma N/A
Completed NCT04470726 - Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma Phase 1/Phase 2